...
首页> 外文期刊>Journal of clinical lipidology >A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment
【24h】

A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment

机译:脂质学家对全球脂质指南和建议的看法,第1部分:脂质治疗目标和风险评估

获取原文
获取原文并翻译 | 示例
           

摘要

Having knowledge of worldwide lipid guidelines and recommendations may provide clinicians a more global perspective on lipid management. This perspective reviews 8 international scientific and/or medical organizations' lipid guidelines, recommendations, and position papers: the National Lipid Association (2014), National Institute for Health and Care Excellence (2014), International Atherosclerosis Society (2013), American College of Cardiology/American Heart Association (2013), Canadian Cardiovascular Society (2013), Japan Atherosclerosis Society (2012), European Society of Cardiology/European Atherosclerosis Society (2012), and Adult Treatment Panel III (2001/2004). Part 1 of this perspective focuses on sentinel components of these lipid guidelines and recommendations as applied to the role of atherogenic lipoprotein cholesterol levels, primary lipid target of therapy, other primary and secondary lipid treatment targets, and assessment of atherosclerotic cardiovascular disease (ASCVD) risk. Part 2 examines goals of lipid-altering therapy to reduce ASCVD events. Both parts 1 and 2 include the author's perspective on sentinel topics. In general, some guidelines and recommendations differ with regard to ASCVD risk assessment and lipid treatment goals. However, lipid guidelines and recommendations have significant concordance regarding the need to reduce atherogenic lipoprotein cholesterol levels, and are in general agreement on the primary lipid treatment targets. Finally, a substantial degree of agreement exists among guidelines and recommendations in their emphasis on the need for aggressive treatment of hypercholesterolemia, for which the predominance of ASCVD outcomes studies suggests statins as the first-line treatment of choice. (C) 2016 National Lipid Association. All rights reserved.
机译:了解全球脂质指南和建议可能会为临床医生提供有关脂质管理的更全面的视角。该观点回顾了8个国际科学和/或医疗组织的脂质指南,建议和立场文件:美国国家脂质协会(2014),美国国家卫生与护理卓越学院(2014),国际动脉粥样硬化学会(2013),美国医学院心脏病/美国心脏协会(2013),加拿大心血管学会(2013),日本动脉粥样硬化学会(2012),欧洲心脏病学会/欧洲动脉粥样硬化学会(2012)和成人治疗小组III(2001/2004)。该观点的第1部分重点介绍了这些脂质指南和建议中的前哨成分,适用于致动脉粥样硬化性脂蛋白胆固醇水平的作用,治疗的主要脂质靶标,其他主要和次要脂质治疗靶标以及对动脉粥样硬化性心血管疾病(ASCVD)风险的评估。第2部分探讨了改变脂质治疗以减少ASCVD事件的目标。第1部分和第2部分均包含作者对定点主题的观点。通常,关于ASCVD风险评估和脂质治疗目标,一些指南和建议有所不同。然而,关于降低动脉粥样硬化性脂蛋白胆固醇水平的需要,脂质指南和建议具有显着的一致性,并且在主要的脂质治疗目标上普遍达成共识。最后,指南和建议在强调积极治疗高胆固醇血症的必要性之间存在着相当程度的共识,对此,ASCVD结果研究的优势表明他汀类药物是首选的一线治疗方法。 (C)2016年国家脂质协会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号